Oxacillin: Difference between revisions

Browse history interactively ← Previous edit Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 07:34, 17 January 2011 editPashihiko (talk \| contribs)Extended confirmed users3,559 editsNo edit summary← Previous edit		Revision as of 07:44, 17 January 2011 edit undoCheMoBot (talk \| contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (report errors or [[user talk:CheMoBotNext edit →
Line 1:		Line 1:
	{{Drugbox		{{Drugbox
			\| Verifiedfields = changed
	\| verifiedrevid = 402514530		\| verifiedrevid = 402514530
	\|IUPAC_name=(2''S'',5''R'',6''R'')-3,3-dimethyl-6--7-oxo-4-thia-1-<br>azabicycloheptane-2-carboxylic acid		\|IUPAC_name=(2''S'',5''R'',6''R'')-3,3-dimethyl-6--7-oxo-4-thia-1-<br>azabicycloheptane-2-carboxylic acid
Line 18:		Line 19:
	\| ChemSpiderID=5873		\| ChemSpiderID=5873
	\|DrugBank=		\|DrugBank=
			\| KEGG_Ref = {{keggcite\|changed\|kegg}}
	\| KEGG = D08307		\| KEGG = D08307
	\|C=19\|H=19\|N=3\|O=5\|S=1		\|C=19\|H=19\|N=3\|O=5\|S=1

Revision as of 07:44, 17 January 2011

Pharmaceutical compound

Oxacillin
Clinical data

ATC code	J01CF04 (WHO) QJ51CF04 (WHO)
Identifiers
IUPAC name (2S,5R,6R)-3,3-dimethyl-6--7-oxo-4-thia-1- azabicycloheptane-2-carboxylic acid
CAS Number	66-79-5
PubChem CID	6098
ChemSpider	5873
UNII	UH95VD7V76
KEGG	D08307
CompTox Dashboard (EPA)	DTXSID8023397
ECHA InfoCard	100.000.577
Chemical and physical data
Formula	C₁₉H₁₉N₃O₅S
Molar mass	401.436 g/mol g·mol
3D model (JSmol)	Interactive image
Density	1.49 g/cm
Boiling point	686.8 °C (1,268.2 °F)
SMILES O=C(O)3N4C(=O)(NC(=O)c2c(onc2c1ccccc1Cl)C)4SC3(C)C
InChI InChI=1S/C19H18ClN3O5S/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27)/t13-,14+,17-/m1/s1 Key:LQOLIRLGBULYKD-JKIFEVAISA-N
(what is this?) (verify)

Oxacillin sodium (trade name Bactocill) is a narrow spectrum beta-lactam antibiotic of the penicillin class.

It was developed by Beecham.

Uses

Oxacillin is a penicillinase-resistant β-lactam. It is similar to methicillin, and has replaced methicillin in clinical use. Another related compound is nafcillin. Since it is resistant to penicillinase enzymes, such as that produced by Staphylococcus aureus, it is widely used clinically in the US to treat penicillin-resistant Staphylococcus aureus. However, resistant strains called oxacillin-resistant Staphylococcus aureus (MRSA/ORSA) are highly prevalent in the U.S. and the U.K.

References

David Greenwood (2008). Antimicrobial drugs: chronicle of a twentieth century medical triumph. Oxford University Press US. pp. 124–. ISBN 9780199534845. Retrieved 18 November 2010.

Antibacterials active on the cell wall and envelope (J01C-J01D)

β-lactams
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)

Penicillins (Penams)

Narrow
spectrum

β-lactamase sensitive (1st generation)	Benzylpenicillin (G) Benzathine benzylpenicillin Procaine benzylpenicillin Phenoxymethylpenicillin (V) Propicillin Pheneticillin Azidocillin Clometocillin Penamecillin
β-lactamase resistant (2nd generation)	Cloxacillin (Dicloxacillin Flucloxacillin) Oxacillin Nafcillin Methicillin

Extended
spectrum

Aminopenicillins (3rd generation)	Amoxicillin Ampicillin (Pivampicillin Hetacillin Bacampicillin Lenampicillin Metampicillin Talampicillin) Epicillin
Carboxypenicillins (4th generation)	Ticarcillin Carbenicillin / Carindacillin Temocillin
Ureidopenicillins (4th generation)	Piperacillin Azlocillin Mezlocillin
Other	Mecillinam (Pivmecillinam) Sulbenicillin

Carbapenems / Penems

Cephems
Cephalosporins
Cephamycins
Carbacephems

1st generation	Cefazolin Cefalexin Cefadroxil Cefapirin Cefazedone Cefazaflur Cefradine Cefroxadine Ceftezole Cefaloglycin Cefacetrile Cefalonium Cefaloridine Cefalotin Cefatrizine
2nd generation	Cefaclor Cefprozil Cefuroxime Cefuroxime axetil Cefamandole Cefonicid Ceforanide Cefuzonam Cephamycin (Cefoxitin Cefotetan Cefminox Cefbuperazone Cefmetazole) Carbacephem (Loracarbef)
3rd generation	Cefixime Ceftriaxone Cefotaxime Antipseudomonal (Ceftazidime Cefoperazone) Cefdinir Cefcapene Cefdaloxime Ceftizoxime Cefmenoxime Cefpiramide Cefpodoxime Ceftibuten Cefditoren Cefotiam Cefetamet Cefodizime Cefpimizole Cefsulodin Cefteram Ceftiolene Oxacephem (Flomoxef Latamoxef)
4th generation	Cefepime Cefozopran Cefpirome Cefquinome
5th generation	Ceftaroline fosamil Ceftolozane Ceftobiprole
Siderophore	Cefiderocol
Veterinary	Ceftiofur Cefquinome Cefovecin

Monobactams

β-lactamase inhibitors

Combinations

Polypeptides

Lipopeptides	Insert into bacterial cell wall causing perforation and depolarization: Daptomycin Surfactin
Other	Inhibits PG elongation and crosslinking: Ramoplanin

Intracellular

Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
DADAL/AR inhibitors (Cycloserine)
bactoprenol inhibitors (Bacitracin)

Other

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This systemic antibiotic-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: